Literature DB >> 3846591

Increasing frequency of penicillin-resistant pneumococci: epidemiological aspects and case-control study.

Y Amitai, M Rotenberg, D Wirtschafter, H Haas, J Michel.   

Abstract

At the Hadassah University Hospital, Mt. Scopus, Jerusalem, the frequency of patients with relatively penicillin-resistant pneumococci (RPRP) isolates has increased from 0.9 to 10.8% during the years 1979-82. Infants and children were particularly involved. Significantly more RPRP isolates were found in those less than 14 years old than in those who were older (P less than 0.005). The determination of susceptibility or relative resistance to penicillin was based on the disk sensitivity method, which remained unchanged throughout the study period. The minimal inhibitory concentration (MIC) to penicillin G was also determined for 20 RPRP isolates and was found to be in the range of relative resistance to penicillin (0.25 to 0.50 micrograms/ml) in all 20 isolates. A case-control study of 16 index patients examined antibiotic usage during the 60 days preceding pneumococcal isolation. Total antibiotic usage was high in both groups (18.8 vs. 8.8 days, P = 0.2); beta-lactam antibiotic usage was significantly higher in the RPRP group than in the control group (13.3 vs. 4.2 days, 0.01 less than P less than 0.02). General prescribing practices, even in nonisolated areas where there is no need for public health programs to dispense prophylactic antibiotics, may produce sufficiently high antibiotic exposures to aid the emergence of RPRP strains.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3846591

Source DB:  PubMed          Journal:  Isr J Med Sci        ISSN: 0021-2180


  2 in total

Review 1.  Pneumococcal resistance to antibiotics.

Authors:  K P Klugman
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

Review 2.  Antibiotic-resistant Streptococcus pneumoniae. Implications for medical practice.

Authors:  E E Wang; J D Kellner; S Arnold
Journal:  Can Fam Physician       Date:  1998-09       Impact factor: 3.275

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.